Netherlands-based ViCentra, the developer of Kaleido insulin patch pump systems, has launched a hybrid closed loop system for automated delivery of insulin for people with type 1 diabetes.

The new system integrates the Kaleido insulin pump with two innovations developed by Diabeloop and Dexcom to offer a flexible, self-learning, and user-friendly approach to manage the disease.

The hybrid closed loop system delivers insulin by utilising the Diabeloop DBLG1 control software, which receives data from the Dexcom G6 continuous glucose monitoring (CGM) sensor.

According to ViCentra, Kaleido users can choose to carry their pump in their pocket or wear it as a patch.

In addition, it comes with two rechargeable pumps that eliminate the need to throw away the pump every three days like other patch pumps.

It also has the option to pause or turn off the pump for sporadic rests and is offered in ten colours, the Dutch insulin patch pumps maker said.

ViCentra CEO Frans Cromme said: “We aim to deliver the best user experience as well as excellent clinical results with our Kaleido insulin pump and our partners.

“Kaleido with DBLG1 and Dexcom G6 improves users’ Time in Range by 16.7%, an achievement that should bring real benefits to people with type 1 diabetes.”

Along with its commercial partner Diabeloop, the company is introducing the hybrid closed loop system in Germany, the Netherlands, and France.

ViCentra has also planned further roll-out to the UK, Italy, and other countries in 2024.

Diabeloop CEO Stephane Majerus said: We are proud to extend our partnership with ViCentra, home of Kaleido, offering people with type 1 diabetes a new level of options in the management of their diabetes.

“This alliance between Diabeloop’s algorithm technology and the ViCentra pump aims to offer people with diabetes the benefits of the Kaleido design combined with our highly performing and proven algorithm.

“Diabeloop’s ultimate goal remains to make available the most advanced solutions to improve the quality of life of people with diabetes, enabling them to devote more time to their passions and daily lives.”